Hansa Biopharma Interim report January-September 2022
· Total Revenue of SEK 67m in the third quarter 2022 · Positive reimbursement decisions received in Poland and Scotland · $70 million raised in non-dilutive financing · Imlifidase included in ESOT guidelines published in Transplant InternationalLund, Sweden October 20, 2022, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to September 2022. Highlights for the third quarter 2022 · Total Q3 revenue of SEK 67m including SEK 23m in product sales and SEK 44m